Objective: To correlate the findings of power Doppler ultrasonography (PDUS) of the prostate with those of site-specific transrectal ultrasonography (TRUS)-guided biopsy.
Patients And Methods: The study comprised 28 patients referred to our institution for TRUS-guided prostate biopsy because of an elevated PSA level and/or abnormal digital rectal examination. PDUS findings were graded 0, 1 or 2; grades 0-1 were considered as negative and grade 2 as positive. The blood volume of each biopsy site was also determined using the mean number (MN) value that represents the average vascularity in a 5-mm square sample. PDUS values were correlated with the histological findings of 147 biopsies with 19 focal lesions.
Results: Grade 2 was assigned to 19 sites, grade 1 to 52 sites, and grade 0 to 76 sites. Fourteen of the 19 PDUS findings of grade 2 sites revealed carcinoma and five were grade 1. Ten of 35 TRUS-positive sites were carcinomas, three benign prostatic hyperplasia (BPH) and 22 normal. The MN value for prostatic carcinoma was 4.33, for BPH 11.7 and for normal tissue 4.7. The overall sensitivity of PDUS was 74%, the specificity 96% and the positive predictive value 74%.
Conclusions: Because TRUS alone cannot detect all cancers, PDUS should be used routinely in all patients undergoing TRUS-guided biopsy, to improve the diagnostic yield of prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1464-410x.2000.00669.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of Smoking Cessation Status and Its Influencing Factors in Patients with Chronic Obstructive Pulmonary Disease.
Int J Chron Obstruct Pulmon Dis
December 2024
State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangdong, People's Republic of China.
Purpose: Chronic obstructive pulmonary disease (COPD) is a common disease with high prevalence, high mortality and high costs across the globe. Small airways are major sites contributing to airway resistance and the small airway disorder (SAD) is frequently implicated in early-stage COPD. Smoking is recognized as the leading cause of COPD and SAD.
View Article and Find Full Text PDFSelumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan.
Jpn J Clin Oncol
January 2025
Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 65-Tsurumai, Showa, Nagoya, 466-8560, Japan.
Objective: In Japan, selumetinib is used in pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic inoperable plexiform neurofibroma (PN). However, there have been no real-world reports on Japanese patients. In this study, we reported a single-center, short-term experience with selumetinib after its approval in Japan.
View Article and Find Full Text PDFScan accuracy of recently introduced wireless intraoral scanners in different fixed partial denture situations.
J Dent
January 2025
Department of Reconstructive Dentistry and Gerodontology, University of Bern, Bern, Switzerland;; Department of Prosthetic Dentistry and Material Science, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Objective: To compare the in vitro scan accuracy (trueness and precision) of recently introduced wireless intraoral scanners (IOSs) to commonly used wired IOSs in different fixed partial denture (FPD) situations.
Methods: Three partially edentulous maxillary models with implants located at different sites (lateral incisors [Model 1]; right canine and first molar [Model 2]; right first premolar and first molar [Model 3]) were digitized with wireless (Primescan 2 [P2] and TRIOS 5 [T5]) and wired (Primescan [P1] and TRIOS 3 [T3]) IOSs (n=14 per IOS-model pair). The models were also digitized with an industrial-grade optical scanner for their reference scans.
Computed tomography scanning in the diagnosis of lower extremity phlebolymphedema.
J Vasc Surg Venous Lymphat Disord
January 2025
The RANE Center for Venous & Lymphatic Diseases, St. Dominic Hospital, Jackson, MS. Electronic address:
Objectives: Phlebolymphedema, the most common cause of secondary lymphedema in Western societies, seldom gets the attention it deserves. Diagnosis is often missed and when evaluated is through lymphoscintigraphy (LSG) which is cumbersome. This study aims to assess the role of computed tomography (CT) scanning in the diagnosis of phlebolymphedema of the lower extremities by comparing CT characteristics to the International Society of Lymphology (ISL) grading system and LSG.
View Article and Find Full Text PDFPhase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.
Cancer Immunol Immunother
January 2025
Liver Cancer Institute, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Introduction: This study aimed to evaluate the safety and preliminary efficacy of serplulimab, a novel programmed death-1 inhibitor, with or without bevacizumab biosimilar HLX04 as first-line treatment in patients with advanced hepatocellular carcinoma.
Methods: This open-label, multicenter phase 2 study (clinicaltrials.gov identifier NCT03973112) was conducted in China and consisted of four treatment groups: group A (serplulimab 3 mg/kg plus HLX04 5 mg/kg, subsequent-line), group B (serplulimab 3 mg/kg plus HLX04 10 mg/kg, subsequent-line), group C (serplulimab 3 mg/kg, subsequent-line) and group D (serplulimab 3 mg/kg plus HLX04 10 mg/kg, first-line).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!